Welcome to our dedicated page for Adma Biologics news (Ticker: ADMA), a resource for investors and traders seeking the latest updates and insights on Adma Biologics stock.
ADMA Biologics, Inc. (NASDAQ: ADMA) is a U.S.-based, end-to-end commercial biopharmaceutical company focused on specialty plasma-derived biologics and other specialty biologics for immunodeficient patients and individuals at risk for certain infectious diseases. The ADMA news feed on Stock Titan aggregates company-issued updates and market-moving announcements so readers can follow developments affecting the ADMA stock and its underlying business.
In its press releases, ADMA regularly reports on quarterly and annual financial results, including total revenue, GAAP net income, adjusted EBITDA and adjusted net income, as well as updates to its financial guidance. The company also issues news on operational milestones such as U.S. Food and Drug Administration (FDA) approvals for its production processes, progress with its yield enhancement production technology, and expansion of its U.S.-based manufacturing and plasma collection infrastructure.
Investors following ADMA news can expect coverage of commercial trends for its FDA-approved plasma-derived products ASCENIV, BIVIGAM and NABI-HB, including reported demand dynamics, payer coverage discussions, and distribution agreements. The company’s updates also address pipeline progress for SG-001, a pre-clinical hyperimmune globulin targeting Streptococcus pneumoniae, along with commentary on intellectual property, supply chain strategy and capital structure actions such as debt refinancing and share repurchase authorizations.
This news page is useful for tracking how ADMA communicates its financial outlook, operational initiatives and product performance over time. Readers interested in the ADMA stock can use the curated news flow to monitor earnings releases, regulatory and manufacturing updates, and other disclosures that the company furnishes through press releases and related filings.
ADMA Biologics (ADMA) announced a poster presentation at the virtual 2021 ISIRV-WHO Conference on October 19-22. The poster details the clinical impact of ASCENIV™, a novel intravenous immune globulin, as a concomitant therapy for a patient with severe respiratory viral disease and COVID-19. ASCENIV, approved by the FDA in April 2019, treats primary humoral immunodeficiency (PI). ADMA manufactures and markets three FDA-approved plasma-derived biologics, focusing on immunocompromised patients and infectious diseases.
ADMA Biologics announced the appointment of Young T. Kwon, Ph.D., to its Board of Directors. Dr. Kwon brings over a decade of experience in corporate finance and strategic advising within the life sciences industry. His previous roles include C-suite positions and leading a $6.5 billion acquisition at Momenta Pharmaceuticals. Chairman Steven Elms emphasized Dr. Kwon's strategic insights as crucial for ADMA's revenue growth in its immunoglobulin product line. Dr. Kwon expressed his commitment to enhancing shareholder value by maximizing the potential of ADMA's biologics manufacturing platform.
ADMA Biologics, Inc. (Nasdaq: ADMA) has announced on-demand access to an educational event at IDWeek 2021 focused on respiratory viral infections. Renowned experts Dr. Michael Ison and Dr. Jolan Walter highlighted the benefits of ASCENIV™, an intravenous immunoglobulin product, in treating pediatric patients with primary immunodeficiency and RSV. The presentation included two illustrative cases demonstrating ASCENIV's efficacy. Approved by the FDA in April 2019, ASCENIV is designed for treating primary humoral immunodeficiency and is backed by proprietary manufacturing methods.
ADMA Biologics has announced an exclusive educational event at IDWeek 2021, focusing on respiratory viral infections, including RSV. The event features expert discussions by Dr. Michael Ison and Dr. Jolan Walter addressing key clinical challenges and introducing ASCENIV™, a novel intravenous immunoglobulin. ASCENIV is FDA-approved for treating primary immune deficiency and is manufactured using a unique plasma donor screening methodology. The session will occur on October 1, 2021, from 1:00 PM to 1:45 PM ET at the IDWeek Learning Lounge.
ADMA Biologics (Nasdaq: ADMA) will participate in a virtual fireside chat at the Cantor Healthcare Conference on September 30, 2021, at 9:20 a.m. ET. Adam Grossman, President and CEO, will lead the discussion. A webcast of the event will be available on the company’s website and archived for 90 days. ADMA specializes in the manufacturing and marketing of plasma-derived biologics, currently offering three FDA-approved products for immunodeficient patients and those at risk of infectious diseases. The company operates an FDA-licensed facility in Boca Raton, Florida.
ADMA Biologics has received FDA approval for its in-house aseptic fill-finish machine, the VanRx SA25, marking a pivotal development in its supply chain strategy. This approval allows ADMA to handle internal fill-finish operations, improving gross margins, patient supply consistency, and reducing production cycle times. The VanRx's advanced design enhances operational control and visibility over product releases. Additionally, the approval opens doors for new contract manufacturing opportunities, positioning ADMA to potentially exceed its financial targets and sustain revenue growth.
ADMA Biologics, Inc. (Nasdaq: ADMA) announced that CEO Adam Grossman will participate in a virtual fireside chat at the Morgan Stanley 19th Annual Global Healthcare Conference on September 9, 2021, at 12:30 p.m. ET. A webcast of this event will be available on ADMA's website and will be archived for 90 days following the event. ADMA specializes in developing plasma-derived biologics aimed at treating immunodeficient patients and is known for FDA-approved products such as BIVIGAM®, ASCENIV™, and NABI-HB®.
ADMA Biologics, Inc. has received FDA approval for its ADMA BioCenters plasma collection facility in Maryville, Tennessee, enhancing its ability to collect human source plasma. This facility started operations in Q4 2020 and is now licensed to introduce plasma into interstate commerce. With a goal of operating 10+ FDA-approved centers by 2024, ADMA aims to secure plasma supply and control manufacturing operations. The center is equipped with advanced technology and aims to employ 50 staff at full capacity, while offering new donors competitive compensation for contributions.
ADMA Biologics reported a record total revenue of $17.8 million for Q2 2021, marking a 129% increase year-over-year, driven primarily by its intravenous immune globulin (IVIG) product portfolio. The company anticipates reaching an annualized revenue run rate of approximately $100 million by the end of 2021. Despite a net loss of $18.9 million for the quarter, improvements in revenue and gross margins were noted. Strategic initiatives, including an expanded production capacity and supply chain enhancements, position ADMA for continued growth and operational efficiencies in the future.
ADMA Biologics (NASDAQ: ADMA) has launched operations at its new plasma collection facility in Conyers, Georgia, marking a significant expansion in its BioCenters network. This center, now the eighth under ADMA, aims to enhance plasma collection efficiency with the introduction of Haemonetics’ Persona® Plasma Collection Solution, expected to increase yield by 9% to 12% per donation. ADMA plans to file a Biologics License Application for this facility in approximately three months, with full FDA review anticipated to take around 12 months. This development is poised to support ongoing revenue growth and profitability.